Nicholas Hoffman & Company LLC. cut its position in Novartis AG (NYSE:NVS) by 1.8% during the first quarter, Holdings Channel reports. The institutional investor owned 9,078 shares of the company’s stock after selling 171 shares during the period. Nicholas Hoffman & Company LLC.’s holdings in Novartis AG were worth $674,000 as of its most recent filing with the SEC.
Other large investors also recently added to or reduced their stakes in the company. Howe & Rusling Inc. boosted its stake in Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares in the last quarter. TCI Wealth Advisors Inc. boosted its stake in Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after buying an additional 230 shares in the last quarter. North Star Investment Management Corp. boosted its stake in Novartis AG by 50.3% in the first quarter. North Star Investment Management Corp. now owns 1,526 shares of the company’s stock worth $113,000 after buying an additional 511 shares in the last quarter. Sowell Financial Services LLC bought a new stake in Novartis AG during the fourth quarter worth approximately $116,000. Finally, Zions Bancorporation boosted its stake in Novartis AG by 21.0% in the fourth quarter. Zions Bancorporation now owns 1,656 shares of the company’s stock worth $120,000 after buying an additional 287 shares in the last quarter. 11.39% of the stock is currently owned by hedge funds and other institutional investors.
Novartis AG (NYSE NVS) opened at 80.83 on Friday. The company has a market cap of $191.21 billion, a P/E ratio of 30.39 and a beta of 0.76. The firm has a 50-day moving average price of $80.16 and a 200-day moving average price of $75.15. Novartis AG has a 12-month low of $66.93 and a 12-month high of $83.58.
Novartis AG (NYSE:NVS) last posted its quarterly earnings results on Tuesday, April 25th. The company reported $1.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.10 by $0.03. The business had revenue of $11.54 billion for the quarter, compared to the consensus estimate of $11.59 billion. Novartis AG had a return on equity of 15.46% and a net margin of 13.10%. The company’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.17 EPS. On average, analysts forecast that Novartis AG will post $4.69 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Nicholas Hoffman & Company LLC. Sells 171 Shares of Novartis AG (NVS)” was posted by WKRB News and is owned by of WKRB News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.wkrb13.com/markets/2229889/nicholas-hoffman-company-llc-sells-171-shares-of-novartis-ag-nvs.html.
A number of equities research analysts have recently commented on the company. Morgan Stanley reissued a “sell” rating on shares of Novartis AG in a research note on Tuesday, June 6th. Vetr cut Novartis AG from a “strong-buy” rating to a “buy” rating and set a $84.66 price objective on the stock. in a research report on Monday, March 13th. Zacks Investment Research raised Novartis AG from a “strong sell” rating to a “hold” rating in a research report on Monday, May 1st. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a research report on Tuesday, March 14th. Finally, BNP Paribas cut Novartis AG from a “neutral” rating to an “underperform” rating in a research report on Tuesday, March 7th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $83.12.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229889/nicholas-hoffman-company-llc-sells-171-shares-of-novartis-ag-nvs.html
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.